Biocon Q2FY23 Revenue at Rs. 2,384 Cr, Up 23 percent; Core EBITDA at Rs. 816 Cr., Up 34 percent Gross R&D Spend at Rs. 252 Crore, Up 52 percent
Biocon Ltd. (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals…
Expect Biocon to become fully integrated biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
Expect Biocon to become fully integrated biosimilars firm post Viatris buy: Kiran…
Business News: Under PLI scheme, Biocon will receive up to Rs 250-crore financial incentives over next six years: Siddharth Mittal
Under PLI scheme, Biocon will receive up to Rs 250-crore financial incentives…
Business News: Serum’s Covidshield Technologies to merge with Biocon Biologics
Serum’s Covidshield Technologies to merge with Biocon Biologics : Rashtra News #Serums…
